ABSTRACT: BACKGROUND AND PURPOSE Pharmacological interventions aimed at restoring the endocannabinoid system functionality have been proposed as potential tools in the treatment of schizophrenia. Based on our previous results suggesting a potential antipsychotic-like profile of the CB1 receptor inverse agonist/antagonist, AM251, here we further investigated the effect of ... Continue Reading